George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Didn't the SP rise significantly on no news in the days preceding the 175p fund raise back in Autumn 2020?
Fact.
WILLIAM22
Posted in: SNG
Posts: 24
Price: 21.00
No Opinion
RE: Monday RNS & price predictions24 Oct 2022 08:42
Why dont people listen ? So frustrating !! RNS will happen next Monday, thats a fact. Maybe people will listen this time.
Patience and patients.
Anyone could. But at what price.
No you wouldn’t. Think about it. Otherwise someone could force a take over by owning 30% of a company. They might only be the 3rd largest shareholder.
Poly being forced to offer 20p is very different from shareholders being forced to accept 20p. Things will have had to go very wrong for the majority of shareholders to be happy to accept 20p, to the extent that Poly would be vastly over-paying.
Andybe4 doth protest too much, me thinks.
Both more, holding now 33% higher.
Scroll down.
At one point RM said 'likely' H2, I assume he's not thinking it will be earlier.
I think I'll wait for the movie.
What’s your figure ?
Would they have sight of the ongoing results though? Not sure how it works with a home trial.
Axe - I was wondering something similar when the Prof said ‘we know it works’, would they have visibility of some home trial results then?
Are interim readouts usually made public?
Dr Lamis Latif, May 2016: "I have been involved in creating new training courses and packs as part of the Harrods Ambassador programme, as well as being a representative for the Luxury Accessories department for the last 6 years...". Now she's de-ramping potentially life-saving respiratory treatments.
Mac - I think your figure is still about right for the general population, interferon deficient patients are just more concentrated in ICU.
In severe cases of Covid the figure is around 15%
https://www.google.co.uk/amp/s/www.bbc.co.uk/news/amp/health-54832563
Blood plasma to treat COVID patients takes a knock
Taking blood plasma from those who've recovered from COVID-19 and using it to treat others has been a big hope during the pandemic, writes Sky News science correspondent Thomas Moore.
But the idea has taken a knock from interim results of a large international study.
The REMAP-CAP study found there was no benefit in using convalescent plasma in seriously ill patients in intensive care.
The researchers have paused treatment following interim analysis of 900 patients.
They will analyse the full data from 2,000 patients, but in the meantime will switch to treating hospitalised patients who are moderately unwell.
Plasma is the part of the blood that contains antibodies against the virus that causes COVID-19. The hope has been that blood from people who have recovered from the disease contains high levels of antibodies that can neutralise the virus and stop tissue damage.
The NHS Recovery Trial of convalescent plasma is continuing, and NHS Blood and Transplant is urging people who've had COVID to keep donating blood.
Convalescent plasma is a precious resource and doctors say it should be targeted at patients who stand to benefit.
What would be the advantage of hiding your position anyway? If you’re planning a takeover perhaps?